Study details
Enrolling now
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Eli Lilly and Company
NCT IDNCT06948422ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
974
Study length
about 2.4 years
Ages
18+
Locations
30 sites in AZ, CA, CT +15
About this study
Researchers are testing a treatment called orforglipron to see if it helps lower blood pressure in people who have both hypertension and obesity or overweight. The trial will last for 883 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Orforglipron
- 2.Take Placebo
PhasePhase 3
DrugOrforglipron
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Cardiology / Heart